160 related articles for article (PubMed ID: 14734634)
1. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage.
Ferrero E; Scabini S; Magni E; Foglieni C; Belloni D; Colombo B; Curnis F; Villa A; Ferrero ME; Corti A
FASEB J; 2004 Mar; 18(3):554-6. PubMed ID: 14734634
[TBL] [Abstract][Full Text] [Related]
2. Regulation of endothelial cell shape and barrier function by chromogranin A.
Ferrero E; Magni E; Curnis F; Villa A; Ferrero ME; Corti A
Ann N Y Acad Sci; 2002 Oct; 971():355-8. PubMed ID: 12438151
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.
Dondossola E; Gasparri AM; Colombo B; Sacchi A; Curnis F; Corti A
Cancer Res; 2011 Sep; 71(17):5881-90. PubMed ID: 21799030
[TBL] [Abstract][Full Text] [Related]
4. Endothelial barrier stabilization by a cyclic tandem peptide targeting VE-cadherin transinteraction in vitro and in vivo.
Heupel WM; Efthymiadis A; Schlegel N; Müller T; Baumer Y; Baumgartner W; Drenckhahn D; Waschke J
J Cell Sci; 2009 May; 122(Pt 10):1616-25. PubMed ID: 19420236
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models.
Colombo B; Curnis F; Foglieni C; Monno A; Arrigoni G; Corti A
Cancer Res; 2002 Feb; 62(3):941-6. PubMed ID: 11830555
[TBL] [Abstract][Full Text] [Related]
7. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation.
Di Comite G; Rossi CM; Marinosci A; Lolmede K; Baldissera E; Aiello P; Mueller RB; Herrmann M; Voll RE; Rovere-Querini P; Sabbadini MG; Corti A; Manfredi AA
J Leukoc Biol; 2009 Jan; 85(1):81-7. PubMed ID: 18832606
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: evidence for disruption of vascular integrity via VE-cadherin down-regulation.
Friedl J; Turner E; Alexander HR
Int J Oncol; 2003 Sep; 23(3):611-6. PubMed ID: 12888895
[TBL] [Abstract][Full Text] [Related]
9. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.
Lee JC; Taylor CV; Gaucher SP; Toneff T; Taupenot L; Yasothornsrikul S; Mahata SK; Sei C; Parmer RJ; Neveu JM; Lane WS; Gibson BW; O'Connor DT; Hook VY
Biochemistry; 2003 Jun; 42(23):6938-46. PubMed ID: 12795588
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
11. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome.
Damle NK; Doyle LV
J Immunol; 1989 Apr; 142(8):2660-9. PubMed ID: 2522965
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A and the endothelial barrier function.
Corti A; Ferrero E
Curr Med Chem; 2012; 19(24):4051-8. PubMed ID: 22834794
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
14. The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression.
Hofmann S; Grasberger H; Jung P; Bidlingmaier M; Vlotides J; Janssen OE; Landgraf R
Eur J Med Res; 2002 Apr; 7(4):171-6. PubMed ID: 12010652
[TBL] [Abstract][Full Text] [Related]
15. The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formation.
Li H; Shi X; Liu J; Hu C; Zhang X; Liu H; Jin J; Opolon P; Vannier JP; Perricaudet M; Janin A; Soria C; Lu H
Cancer Gene Ther; 2010 Oct; 17(10):700-7. PubMed ID: 20559333
[TBL] [Abstract][Full Text] [Related]
16. Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice.
Hornyak SC; Orentas DM; Karavodin LM; Gehlsen KR
Vascul Pharmacol; 2005 Mar; 42(4):187-93. PubMed ID: 15820445
[TBL] [Abstract][Full Text] [Related]
17. [A study of inhibitory effect of chromogranin A derived peptide CGA(47 _ 66) on hyper - permeability of endothelium induced by serum of septic patient].
Gu NN; Zhang D; Luo L; Chen XY; Xie M; Liu JL; Jiang LP
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Dec; 25(12):715-9. PubMed ID: 24620384
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A.
Hendy GN; Bevan S; Mattei MG; Mouland AJ
Clin Invest Med; 1995 Feb; 18(1):47-65. PubMed ID: 7768066
[TBL] [Abstract][Full Text] [Related]
19. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate.
LeBerthon B; Khawli LA; Alauddin M; Miller GK; Charak BS; Mazumder A; Epstein AL
Cancer Res; 1991 May; 51(10):2694-8. PubMed ID: 2021947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
